Pune, India -- (SBWIRE) -- 05/14/2018 -- Performance Enhancing Drugs Market - Key Players

The key players for the global performance enhancing drugs market are:

Taj Pharmaceuticals Limited. (India)
Balkan Pharmaceuticals. (Europe)
Bayer AG (Europe)
AstraZeneca (Europe)
Novo Nordisk A/S (Europe)
BrainAlert, LLC (U.S.)
Douglas Laboratories. (U.S.)
Onnit Labs, LLC. (U.S.)
Eli Lilly and Company. (U.S.).

Performance Enhancing Drugs Market - Overview

Performance enhancing drugs are chemical agents designed to provide an advantage in athletic performance. Muscle enlargement, increased blood's oxygen carrying capacity are some of the effects induced by the consumption of the performance enhancing drugs. The Global Performance Enhancing Drugs Market is expected to grow at an approximate CAGR of 4.8%.

Growing use of the anabolic steroids by athletes, increasing use of steroids for the treatment of medical conditions such as, pain management, anaemia, and certain kinds of breast cancer besides others is expected to fuel the market growth

Now there is new horizon & huge untapped market have been identified for performance enhancing drugs, as the drugs can be used by army to create an army of 'super soldiers. SOCOM wants to use performance-enhancing drugs to create an army of 'super soldiers.

U.S. Special Operations Command is weighing the use of nutritional supplements or even performance-enhancing drugs to push the abilities and endurance of its forces beyond current human limits, according to a report from defence news.

While special operations forces already have access to specialized resources, like dieticians & physical therapists, SOCOM is looking to increase their ability to tolerate pain, recover from injuries, and remain physically able in challenging environments. SOCOM was exploring nutritional supplements, other substances were in consideration as well.

One goal of the research to develop what Defence news referred to as "super soldiers" would be to expand troops' ability to operate in places not well suited for human's high altitudes or underwater in particular

Performance Enhancing Drugs Market - Intended Audience

Pharmaceutical Companies
Sports Industries
Biotechnological Institutes
Medical Laboratories
Market Research and Consulting Service Providers

Click to Get Sample Report @
https://www.marketresearchfuture.com/sample_request/4695 .

Performance Enhancing Drugs Market - Segmentation

The Global Performance Enhancing Drugs Market is segmented on the basis of types, products, and end users.
On the basis of types, the market is segmented into ergogenic aids, nootropic, and others. The ergogenic aids segment by types is sub-segmented into anabolic steroids, dehydroepiandrosterone (DHEA), human growth hormone, and others. The nootropic segment by types is further segmented into racetams, ampakines, choline & acetylcholine intermediates, and others. On the basis of the products, the market is categorized into pills, injections, patches, and others. On the basis of the end users, the market is segmented into athletes, body builders, students, militaries, and others.

Performance Enhancing Drugs Market - Regional Analysis

The Americas dominates the global performance enhancing drugs market due to the presence of well-developed economies like the U.S. and Canada, which have high per capita healthcare expenditure. In 2017, according to the American Cancer Society in the U.S., about 252,710 new cases of invasive breast cancer were diagnosed in women. Moreover, it is predicted that by the end of 2017, 40,610 women would die from breast cancer. This is projected to boost the market growth during the forecasted period because certain anabolic steroids can be used for the treatment of certain types of breast cancer.

Europe is the second largest performance enhancing drug market, which is followed by Asia Pacific. Availability of funds for research and increasing acceptance of the performance enhancing drugs within the region likely to boost the market growth during the forecasted period.

Asia Pacific is the fastest growing region for the market due to the increasing acceptance of the performance enhancing drugs, presence of huge opportunity in untapped the market, and presence of developing economies within the region such as China and India.

Get Unbelievable Discount on Report @
https://www.marketresearchfuture.com/check-discount/4695 .

On the other hand, the Middle East & Africa has the least share in the global performance enhancing drugs market due to presence of poor economy and stringent government policies, especially, in Africa region. Majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and rising healthcare expenditure.

Major Table of Content

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

List of Tables

Table 1 Performance Enhancing Drugs Industry Synopsis, 2017 – 2023

Table 2 Global Performance Enhancing Drugs Market Estimates and Forecast, 2017 – 2023, (USD Million)

Table 3 Global Performance Enhancing Drugs Market by Region, 2017 – 2023, (USD Million)

List of Figures

Figure 1 Research Process

Figure 2 Segmentation for Global Performance Enhancing Drugs Market

Figure 3 Segmentation Market Dynamics for Global Performance Enhancing Drugs Market

Continued….

To Know More Enquire @ https://www.marketresearchfuture.com/enquiry/4695 .

About Market Research Future
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.